sanofi-adr (SNY) Key Developments
Evotec AG and Sanofi Sign Definitive Agreement for Major Multi-Multi-Component Strategic Alliance
Mar 20 15
Evotec AG announced the signing of a definitive agreement for a major multi-component strategic alliance over the next five years with Sanofi. The transaction is expected to close on 31 March 2015. The signing successfully concludes the exclusive negotiations for a major multi-component strategic collaboration between the two companies entered and announced on 02 December 2014. The definitive agreement defines the conditions under which Evotec and Sanofi intend to jointly progress a portfolio of primarily oncology related projects, including five advanced, pre-clinical projects and further discovery-stage assets, to IND (Investigational New Drug) status or other value inflection points before partnering them. The collaboration will result in a minimum guaranteed commitment from Sanofi to Evotec of EUR 250 million over the next five years, including more than EUR 40 million upfront cash payment.
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(R) (lixisenatide)
Mar 19 15
Sanofi announced top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety. ELIXA full results will be presented on June 8, 2015, at the American Diabetes Association 75th Scientific Sessions in Boston by the ELIXA steering committee. The results will also be included in the U.S. New Drug Application of lixisenatide, which is on track to be resubmitted to the U.S. Food and Drug Administration in the third-quarter of 2015.
Sanofi and Regeneron Pharmaceuticals, Inc. Announce Results of a Phase 3 Trial of Praluent
Mar 15 15
Sanofi and Regeneron Pharmaceuticals, Inc. announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or 'bad' cholesterol) by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks. ODYSSEY LONG TERM evaluated Praluent 150 mg (n=1,553) every two weeks compared to placebo (n=788) in patients who were at high cardiovascular (CV) risk and who were receiving maximally-tolerated statin therapy with or without other lipid-lowering treatment. The trial included patients with heterozygous familial hypercholesterolemia (HeFH) (n=276 Praluent, n=139 placebo). Patients received 78 weeks of treatment followed by an eight-week safety assessment. Patients self-administered a subcutaneous injection every two weeks via a pre-filled syringe.
Sanofi, Board Meeting, Mar 03, 2015
Mar 13 15
Sanofi, Board Meeting, Mar 03, 2015. Agenda: To consider the compensation of the Chairman and the CEO.
Sanofi Appoints Robert Castaigne as Audit Committee Chairman
Mar 7 15
Sanofi announced the appointment of Robert Castaigne as Chairman of its Audit Committee. Mr. Castaigne succeeds Dr. Klaus Pohle who has chaired Sanofi's Audit Committee since 2004. This appointment is effective as of the Sanofi Board of Directors meeting on March 3, 2015. Dr. Pohle remains a member of the Sanofi Board of Directors. He also has held various positions at the Total group including Chief Financial Officer and was a member of the Executive Committee. He has been a member of the Sanofi Board of Directors since 2000 and a member of its Audit Committee since 2008.